Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Biosimilars Market Be Worth By 2029?

The size of the biosimilars market has seen a quick expansion in recent years. It is anticipated to rise from $18.65 billion in 2024 to $21.85 billion in 2025, with a compound annual growth rate (CAGR) of 17.2%. Factors that contributed to the growth in the historic period include a rising incidence of cancer, robust economic development in upcoming markets, a boost in pharmaceutical research and development costs, elevated healthcare spending, increasing government schemes, a solid drug pipeline, the affordability of biosimilars, and a surge in patent expirations.

The biosimilars market is projected to experience significant expansion in the upcoming years, with a projected size of $41.34 billion in 2029, and a compound annual growth rate (CAGR) of 17.3%. Various factors contribute to this anticipated growth in the forecast period, including an uptick in cancer incidence rates, growing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), increased healthcare spending, the promising potential of emerging markets, advancements in technology, widespread use of biological drugs, an aging demographic, and improved access to healthcare. The primary trends anticipated during the forecast period are a concentration on vigorous R&D activities for creating effective and innovative pharmaceuticals, an emphasis on mergers and acquisitions for growth strategies, a focus on forming strategic alliances, increasing investment, and the incorporation of artificial intelligence.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Growth-Enabling Forces Are Impacting The Biosimilars Market?

The anticipated escalation in frequency of long-suffering ailments, including arthritis, asthma, and cancer, is assumed to be a key engine propelling the growth of the biosimilars market. Contributing factors to the surge in these chronic conditions include lengthy work schedules, lack of physical exercise, and poor dietary and drinking practices, with biosimilars being increasingly utilized to manage these afflictions. Biosimilars work by prompting the immune system’s response against cancer cells thereby enabling the immune system to purge cancer cells. As per an article by the United Nations, the ratio of worldwide fatalities attributable to chronic diseases is predicted to rise to 70% of all deaths by 2030. The universal chronic disease burden is also foreseen to surge to around 60%. Consequently, this upswing in chronic illnesses is likely to stimulate demand for biosimilars, in turn, catalyzing the expansion of the biosimilars market.

How Is The Biosimilars Market Segmented Across Key Categories?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

What Key Trends Are Driving Growth In The Biosimilars Market?

In the biosimilars market, leading companies are accentuating on the development of innovative products to maintain their competitiveness. AMJEVITA has emerged as the first U.S. biosimilar to Humira, a frequently used medicine by over a million patients struggling with certain severe inflammatory diseases. Amgen Inc., a biotechnology firm from the US, unveiled AMJEVITA (adalimumab-atto) in January 2023. It is a biosimilar to Humira (adalimumab) and is now accessible in the US. It is available at a wholesale acquisition cost, which is listed at 55% lower than the existing list price for Humira. Additionally, AMJEVITA also has a list price that is 5% less than the current Humira list price.

Who Are The Major Stakeholders Operating In The Biosimilars Market?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

How Do Regional Dynamics Influence The Biosimilars Market Performance?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model